Enliven Therapeutics (ELVN) affiliate files to sell 45,000 shares via Jefferies
Rhea-AI Filing Summary
Enliven Therapeutics, Inc. filed a Section 144 notice reporting proposed and recent sales of Common Stock by an affiliate through Jefferies LLC.
The filing lists a proposed sale of 45,000 shares with a related value of $1,401,750.00 and trade/broker details noting Nasdaq and a filing date of 03/25/2026. The filing also discloses prior sales by Helen Collins of 45,000, 29,871, 10,129, and 5,000 shares on 02/17/2026, 03/09/2026, 03/10/2026, and 03/17/2026 respectively, with the dollar amounts shown for each transaction.
Positive
- None.
Negative
- None.
Insights
Section 144 notice shows affiliate sales and a proposed 45,000-share offering via Jefferies.
The filing lists a proposed sale of 45,000 Common shares with a related amount of $1,401,750.00 and identifies Jefferies LLC as the broker. It records earlier sales by Helen Collins across four dates totaling disclosed proceeds.
Cashflow treatment and any trading method beyond brokered transactions are not detailed; subsequent Form 4/144 updates could state actual execution details or method changes.
Affiliate disposition is recorded; filings document both proposed and prior executed sales.
The notice ties multiple executed sales by Helen Collins to specific dates and gross proceeds, providing a clear historical trace of disposals. The proposed sale is routed through Jefferies, listed with a Nasdaq execution context.
Compliance watchers should expect any final sale confirmations or Rule 144 eligibility statements in follow-up filings; the excerpt does not state holding-period or resale-limitation qualifiers.